# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA2423147 | B | Antagonist activity at P2Y12 receptor in human whole blood assessed as inhibition of ADP-induced platelet aggregation after 5 mins by residual platelet count assay | Homo sapiens | 12 | tissue-based format | Scientific Literature | ||
2. | ALA2423148 | F | Antagonist activity at P2Y12 receptor (unknown origin) expressed in CHO cell membrane by [35S]GTPgammaS binding assay | Homo sapiens | 21 | cell-based format | Scientific Literature | ||
3. | ALA2423149 | B | Displacement of [125I]-AZ11931285 from P2Y12 receptor (unknown origin) expressed in CHO cell membrane after 1 hr by scintillation counting analysis | Homo sapiens | 22 | cell-based format | Scientific Literature | ||
4. | ALA2423150 | F | Antithrombotic activity in Beagle dog modified Folts model assessed as inhibition of ADP-induced platelet aggregation administered as bolus infusion measured after 30 mins | Canis lupus familiaris | 2 | organism-based format | Scientific Literature | ||
5. | ALA2424011 | A | Therapeutic index, ratio of ED50 for antithrombotic activity in Beagle dog modified Folts model to dose required to increase in bleeding time by 3.5 fold in Beagle dog modified Folts model | Canis lupus familiaris | 4 | organism-based format | Scientific Literature | ||
6. | ALA2424012 | T | Toxicity in Beagle dog modified Folts model assessed as dose required to increase in bleeding time by 3.5 fold compound administered as bolus infusion | Canis lupus familiaris | 2 | organism-based format | Scientific Literature | ||
7. | ALA2424013 | F | In vivo antithrombotic activity in Beagle dog modified Folts model assessed as increase in blood flow administered as bolus infusion measured after 30 mins | Canis lupus familiaris | 4 | organism-based format | Scientific Literature | ||
8. | ALA2424015 | A | Half life in Beagle dog at 2 mg/kg, po | Canis lupus familiaris | 4 | organism-based format | Scientific Literature | ||
9. | ALA2424017 | A | Oral bioavailability in Beagle dog at 2 mg/kg | Canis lupus familiaris | 4 | organism-based format | Scientific Literature | ||
10. | ALA2424020 | A | Clearance in Beagle dog at 2 mg/kg, iv | Canis lupus familiaris | 4 | organism-based format | Scientific Literature | ||
11. | ALA2424021 | A | Plasma protein binding in dog assessed as fraction unbound level by equilibrium dialysis method | Canis lupus familiaris | 6 | cell-free format | Scientific Literature | ||
12. | ALA2424022 | A | Inhibition of human recombinant CYP3A4 | Homo sapiens | 10 | single protein format | Scientific Literature | ||
13. | ALA2424023 | A | Inhibition of human recombinant CYP2C9 | Homo sapiens | 10 | single protein format | Scientific Literature | ||
14. | ALA2424024 | P | Dissociation constant, pKa of the compound | 4 | small-molecule physicochemical format | Scientific Literature | |||
15. | ALA2424025 | A | Intrinsic clearance in dog liver microsomes by LC/MS analysis | Canis lupus familiaris | 9 | microsome format | Scientific Literature | ||
16. | ALA2424026 | A | Permeability across apical to basolateral side in human Caco2 cells by LC/MS analysis | Homo sapiens | 17 | cell-based format | Scientific Literature | ||
17. | ALA2424027 | P | Kinetic solubility of the compound at pH 6.8 after 16 hrs by LC-UV/MS analysis | 9 | small-molecule physicochemical format | Scientific Literature | |||
18. | ALA2424028 | P | Lipophilicity, log D of the compound at pH 6.8 by chromatographic method | 21 | small-molecule physicochemical format | Scientific Literature |